Risankizumab improves remission rates of ulcerative colitis patients, trials suggest

Getty/RealPeopleGroup

By Olivia Bowthorpe

Patients with moderate to severe ulcerative colitis may benefit from a new form of monoclonal antibody that improved remission rates in two randomised trials.

Risankizumab, sold as Skyrizi, significantly increased the chance of remission, compared with placebo, as both an induction and maintenance therapy.